



Metabolomic investigations in cerebrospinal fluid of Parkinson's disease

Willkommen, Desiree ; Lucio, Marianna ; Moritz, Franco ; Forcisi, Sara ; Kanawati, Basem ; Smirnov, Kirill S ; Schroeter, Michael ; Sigaroudi, Ali ; Schmitt-Kopplin, Philippe ; Michalke, Bernhard

Abstract: The underlying mechanisms of Parkinson's disease are not completely revealed. Especially, early diagnostic biomarkers are lacking. To characterize early pathophysiological events, research is focusing on metabolomics. In this case-control study we investigated the metabolic profile of 31 Parkinson's disease-patients in comparison to 95 neurologically healthy controls. The investigation of metabolites in CSF was performed by a 12 Tesla Solarix Fourier transform-ion cyclotron resonance-mass spectrometer (FT-ICR-MS). Multivariate statistical analysis sorted the most important biomarkers in relation to their ability to differentiate Parkinson versus control. The affected metabolites, their connection and their conversion pathways are described by means of network analysis. The metabolic profiling by FT-ICR-MS in CSF yielded in a good group separation, giving insights into the disease mechanisms. A total number of 243 metabolites showed an affected intensity in Parkinson's disease, whereas 15 of these metabolites seem to be the main biological contributors. The network analysis showed a connection to the tricarboxylic cycle (TCA cycle) and therefore to mitochondrial dysfunction and increased oxidative stress within mitochondria. The metabolomic analysis of CSF in Parkinson's disease showed an association to pathways which are involved in lipid/ fatty acid metabolism, energy metabolism, glutathione metabolism and mitochondrial dysfunction.

DOI: <https://doi.org/10.1371/journal.pone.0208752>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-161526>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Willkommen, Desiree; Lucio, Marianna; Moritz, Franco; Forcisi, Sara; Kanawati, Basem; Smirnov, Kirill S; Schroeter, Michael; Sigaroudi, Ali; Schmitt-Kopplin, Philippe; Michalke, Bernhard (2018). Metabolomic investigations in cerebrospinal fluid of Parkinson's disease. PLoS ONE, 13(12):e0208752.

DOI: <https://doi.org/10.1371/journal.pone.0208752>

RESEARCH ARTICLE


Metabolomic investigations in cerebrospinal fluid of Parkinson's disease

Desiree Willkommen¹*, Marianna Lucio¹*, Franco Moritz¹, Sara Forcisi¹, Basem Kanawati¹, Kirill S. Smirnov¹, Michael Schroeter², Ali Sigaroudi^{3,4}, Philippe Schmitt-Kopplin^{1,5}, Bernhard Michalke¹

1 Analytische BioGeoChemie, Helmholtz Zentrum München, Neuherberg, Germany, **2** Klinik und Poliklinik für Neurologie, Uniklinik Köln, Köln, Germany, **3** Klinik für Klinische Pharmakologie und Toxikologie, Universitätsspital Zürich, Zürich, Switzerland, **4** Institut I für Pharmakologie, Zentrum für Pharmakologie, Uniklinik Köln, Köln, Germany, **5** Analytische Lebensmittelchemie, Wissenschaftszentrum Weihenstephan, TU München, Freising, Germany

* These authors contributed equally to this work.

* desiree.willkommen@helmholtz-muenchen.de (DW); marianna.lucio@helmholtz-muenchen.de (ML)



OPEN ACCESS

Citation: Willkommen D, Lucio M, Moritz F, Forcisi S, Kanawati B, Smirnov KS, et al. (2018) Metabolomic investigations in cerebrospinal fluid of Parkinson's disease. PLoS ONE 13(12): e0208752. <https://doi.org/10.1371/journal.pone.0208752>

Editor: Anna Halama, Weill Cornell Medical College in Qatar, QATAR

Received: August 2, 2018

Accepted: November 21, 2018

Published: December 10, 2018

Copyright: © 2018 Willkommen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing interests: Michael Schroeter got personal compensation for talks and advisory boards by Biogen, Sanofi/Genzyme, Grifols, Merck, Miltenyi Biotec, Novartis, Roche. This does not alter our adherence to PLOS ONE policies on

Abstract

The underlying mechanisms of Parkinson's disease are not completely revealed. Especially, early diagnostic biomarkers are lacking. To characterize early pathophysiological events, research is focusing on metabolomics. In this case-control study we investigated the metabolic profile of 31 Parkinson's disease-patients in comparison to 95 neurologically healthy controls. The investigation of metabolites in CSF was performed by a 12 Tesla Solarix Fourier transform-ion cyclotron resonance-mass spectrometer (FT-ICR-MS). Multivariate statistical analysis sorted the most important biomarkers in relation to their ability to differentiate Parkinson versus control. The affected metabolites, their connection and their conversion pathways are described by means of network analysis. The metabolic profiling by FT-ICR-MS in CSF yielded in a good group separation, giving insights into the disease mechanisms. A total number of 243 metabolites showed an affected intensity in Parkinson's disease, whereas 15 of these metabolites seem to be the main biological contributors. The network analysis showed a connection to the tricarboxylic cycle (TCA cycle) and therefore to mitochondrial dysfunction and increased oxidative stress within mitochondria. The metabolomic analysis of CSF in Parkinson's disease showed an association to pathways which are involved in lipid/ fatty acid metabolism, energy metabolism, glutathione metabolism and mitochondrial dysfunction.

Introduction

Parkinson's disease (PD) is a severe neurodegenerative disease with a prevalence of 0.6% in 65 to 69 years old population that increases up to 3.5% in the population between 85 and 89 years old [1]. The clinical diagnosis relies on the typical cardinal symptoms: resting tremor, bradykinesia, and rigidity. Hallmark of pathophysiological events is the progressive loss of dopaminergic neurons, but symptoms appear when at least 60–80% of dopaminergic neurons are lost [2]. Up to date, early diagnostic biomarkers are lacking [3], therefore emerging interest is moving

sharing data and materials. The other authors declare no conflict of interest.

Abbreviations: ARA, arachidonic acid; DG, diacylglycerol; DGLA, dihomo- γ -linolenic acid; ESI, electrospray ionization; ETC, electron transport chain; FT-ICR-MS, Fourier transform-ion cyclotron resonance-mass spectrometry; GSH, glutathione; GSSG, glutathione disulfide; MDA, malondialdehyde; MDB, mass difference building block; MDEA, mass difference enrichment analysis; MDIN, mass difference network; m/z, mass-to-charge-ratio; OPLS-DA, Orthogonal Projections to Latent Structure-Discriminant Analysis; PC, phosphatidylcholine; PD, Parkinson's disease; PE, phosphatidylethanolamine; PG, prostaglandin; PPE, protein precipitation extraction; PUFA, polyunsaturated fatty acid; ROC, receiver operating characteristic; ROS, reactive oxygen species; sPLS-DA, sparse Partial Least Square-Discriminant Analysis; SOD, superoxide dismutase; TCA, tricarboxylic acid.

towards metabolic changes due to disease. Consequently, recent research is focusing on metabolomics to uncover early metabolic events in PD by the use of different analytical technologies.

LeWitt *et al.* applied ultrahigh performance liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry for the analysis of plasma and cerebrospinal fluid (CSF) metabolome of 49 PD affected patients [4]. They identified prognostic plasma-biomarkers. Burté *et al.* identified, by MS-based techniques, 20 metabolites in human serum associated with PD and mild cognitive impairment [5]. The identified metabolites were mainly linked to the fatty acid oxidation pathway. A metabolic profiling approach was implemented for CSF by the use of NMR resulting in 15 metabolites, predominantly amino acids, which distinguished between PD and control [6]. The mouse brain metabolome of the disease manganism—a Mn-related Parkinsonian disease—was investigated by Fourier transform-ion cyclotron resonance-mass spectrometry (FT-ICR-MS) [7, 8], a MS-based technique that offers ultra-high resolution and mass accuracy. This technique allows for the concurrent detection of thousands of metabolites in a complex matrix [9] as well as the assignment of putative molecular formulas [10, 11] to each experimentally detected feature. Changes in amino acid, fatty acid, glutathione, glucose and purine/pyrimidine metabolisms were detected, showing an increase in oxidative stress and in inflammation markers [7, 8]. A recent review summarizes the results of metabolic profiling studies in Parkinson's disease [12].

Generally, the metabolomics' investigations can be targeted or non-targeted. A targeted investigation is restricted to a specific compound or a class of compounds whereas non-targeted analysis provides a comprehensive chemical characterization of a complex bio/chemical system [13]. The analysis by FT-ICR-MS is semi-quantitative and considers the intensity of each detected feature as a measure of their concentration. Therefore, this technique is suitable for the profile screening in a discovery oriented way. For the first time, to our knowledge, a non-targeted FT-ICR-MS was applied to get a not restricted deeper knowledge about the biochemical pathways involved in PD. A suitable liquid to reflect metabolomic changes in neurodegenerative diseases is CSF, which is in close contact to the brain [14, 15].

A machine learning approach sorted the most important compounds in relation to their ability to differentiate PD and control. An additional network analysis revealed mass differences of the selected, most important compounds for supplemental information about ongoing processes. Notably, the network analysis showed a connection to the tricarboxylic acid (TCA) cycle, to mitochondrial dysfunction, and increased oxidative stress within mitochondria. With this unique combination of metabolic profiling and network analysis, the investigations provided deeper insights into ongoing disease mechanisms and the major effectors of the disease. Especially oxidative stress (e.g. lipid peroxidation and changes in antioxidant compounds like glutathione) and neuroinflammation (e.g. arachidonic acid) are known to be involved in PD [16] and hence are the main focus of our investigation. Alterations may be due to primary disease processes as well as due to compensatory or reactive (e.g. inflammatory) mechanisms and epiphenomena.

Materials and methods

Chemicals

The purchased chemicals are: MeOH from CHROMASOLV LC-MS (Sigma-Aldrich, St. Louis, USA) and L-Arginine from Sigma Aldrich (>98% purity, St. Louis, USA).

Study participants

A total of 126 CSF-samples were taken by standardized lumbar puncture at the Cologne University Hospital and were originally not intended for scientific use, but stored in the biobank

of the hospital. The procedure of lumbar puncture was performed without problems and patients recovered quickly. Thirty-one of the CSF-samples were taken from patients diagnosed with PD and 95 samples derived from neurologically healthy controls (Table 1). The control patients underwent lumbar puncture after neurological symptoms (e.g. headache, dizziness) to exclude diseases of the central nervous system. Regarding the medication of the PD-patients, the patients are divided into 18 patients without any PD-specific medication, 11 patients with PD-specific medication (one or more of the following drugs: L-dopa, Madopar, Clarium, Sifrol/Pramipexol, Azilect, amantadine, and Artane), and two patients had electrodes for deep brain stimulation.

After lumbar puncture the samples remained at room temperature up to 6 hours for routine diagnostics. Subsequently, the samples were stored at $-20 \pm 1^\circ\text{C}$ temporary and later at $-80 \pm 1^\circ\text{C}$ until measurement. The count of erythrocytes was determined in a semi-quantitative manner in a counting chamber (negative = no erythrocytes, isolated < 5 erythrocytes/ μL , + < 90 erythrocytes/ μL , ++ > 90 erythrocytes/ μL , +++ > 350 erythrocytes/ μL , plentiful = overlying erythrocyte layers). Only samples with negative or isolated erythrocytes were involved in the study. The study was approved by the Ethics Committee of the University Cologne (09.12.2014, no. 14–364). All patients consented to scientific use of their CSF-samples.

Sample preparation

Prior to FT-ICR-MS analyses a protein precipitation extraction (PPE) was performed. The protocol was adapted from Forcisi et al. [9]. The frozen CSF-samples were thawed on ice and vortex-mixed for 30 seconds prior to treatment. Ice-cold MeOH (320 μL) was added to an 80 μL aliquot of each CSF sample. The samples were vortex-mixed for 30 s at room temperature and centrifuged at 18,900 g for 10 min at 4°C . The recovered supernatant was diluted (dil. factor: 1/70) in MeOH prior to FT-ICR-MS analysis.

FT-ICR-MS measurement

Ultrahigh resolution mass spectra were acquired by means of FT-ICR-MS (Solarix, Bruker, Bremen, Germany), equipped with a 12 Tesla superconducting magnet (Magnex Scientific, Varian Inc., Oxford, UK) and an electrospray ionization (ESI) source (Apollo II, Bruker Daltonics, Bremen, Germany). An external calibration was performed by analysis of a 3 mg/L arginine solution in MeOH with calibration errors below 0.1 ppm. All measurements were performed in negative ionization mode and ion accumulation time of 300 ms for higher sensitivity. The injection flow rate was 2 $\mu\text{L}/\text{min}$ for electrospray. Operating temperature was 180°C for rapid solvent evaporation inside the electrospray. The ESI nebulizer gas flow rate was 2 L/min and the dry gas flow rate 4 L/min. The spectra were recorded in a mass-to-charge-ratio (m/z) range of 123–1000. For the generation of each mass spectrum 300 scans were acquired. A time-domain transient of 4 MW size was produced for each acquisition, which yielded ultra-high resolution for all signals, which are of metabolomic interest.

Table 1. Characteristics of PD and controls.

	Parkinson Patients	Healthy controls
Number of CSF-samples	n = 31	n = 95
Age (years)	65.5 ± 12.2	44.9 ± 17.3
Sex (f/m)	9/22	59/36
duration of disease (years)	0.87 ± 2.2	/

<https://doi.org/10.1371/journal.pone.0208752.t001>

Data pre-treatment and statistics

The spectra were calibrated with an in-house calibration tool developed in Matlab (Release 2016a, The MathWorks, Inc., Natick, Massachusetts, US). The main principle is based on estimating the most probable calibration curve given the density map describing the behavior of a mass accuracy along the considered mass range. The extracted peaks were aligned within a 1 ppm tolerance window and stored in a data matrix [17]. The masses with a frequency below 10% were not considered during further data mining, the intensities of absent masses were set to zero in the related samples. We applied the in-house developed software *Netcalc* to remove potential spectral noise and isotope peaks. This software assigns molecular formulas to the aligned *m/z*-peaks based on a mass difference between the detected features [18]. Moreover, additional annotation was performed using the web server MassTRIX [19, 20] with *Homo sapiens* as reference organism. All annotations were stored in the original data matrix. The assignment of a molecular formula to each *m/z* values was performed by molecular formula propagation through mass difference networks (MDiN). Here, *m/z* features (nodes) were connected by mass differences (edges) with corresponding molecular formula labels (e.g. $\Delta m/z = 14.01565 \rightarrow \Delta CH_2$) and random walks starting from known peaks updated the molecular formulas of yet unassigned *m/z* peaks. The network was optimized to correct conflicting relationships and to closely follow the intrinsic *m/z*-error distribution of a spectrum for which reason this so-called Netcalc-algorithm is considered as an unsupervised filter that reduces the data size and reveals an underlying biochemical network structure inside the data set [21]. In order to improve the efficiency of the classification (Parkinson versus controls) and reduce possible overfitting and noise, we preprocessed the entire dataset applying the ReliefF algorithm [22]. The algorithm identified a subset of variables (in total 243 masses) that was able to maximize the classification accuracy of the subsequent classification models. The features' selection was based on the highest rank value attributed to each variable by the software. For each masses (stored in the S2 Table) we reported, the sensitivity, the specificity, the positive predictive value (PPV) and the negative predictive value (NPV). A sparse Partial Least Squares-Discriminant Analysis (sPLS-DA) was built in order to assign the respective metabolites for each class from the list of 243 masses. sPLS-DA imposes sparseness within the latent components to improve variables selection while performing simultaneous dimension reduction. A 7-fold cross-validation together with the receiver operating characteristic curve (ROC) was chosen to evaluate the classification performance. For this model, the Balanced Error Rate (BER) has been calculated to evaluate the performances. BER is appropriate in case of an unbalanced number of samples per class as it calculates the average proportion of wrongly classified samples in each class [23]. For the classification model we used the MixOmics package and for the values presented in S2 Table (sensitivity, specificity, PPV and NPV) we have used reportROC package (RStudio Version 1.0.136 – 2009–2016 RStudio, Inc.) Moreover, an Orthogonal Projections to Latent Structures-Discriminant Analysis (OPLS-DA) model was applied to have another classification model and to describe the orthogonal variance. The performance of the fit and the prediction were evaluated with the R^2 and Q^2 values. Moreover, we provide the p-value for Analysis of Variance of Cross-Validation Estimators. Those elaborations were done in SIMCA 13.0.3.0 (Umetrics, Umeå, Sweden).

For the most important metabolites we did an analysis of covariance (ANCOVA) testing the significance for the interactions of the factor (Parkinson vs. control) with age and also with gender. Then we calculated all the p-values (adjusted by Dunnett test) of the differences between Parkinson vs. control (being an unbalanced experimental design we chose to compare the least squares means) controlled by gender (listed in Table 2). The elaboration was done using the general linear model (GLM) analysis in SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Additionally, a mass difference enrichment analysis (MDEA) was performed following Moritz *et al.* [24]. The list of mass difference building blocks (Δm), investigated for enrichment

Table 2. Most important neutral masses to distinguish between PD and controls with respective molecular formula, possible compounds assignment and mean intensity \pm standard deviation (SD). The p-values are the result of the general linear model (GLM) adjusted with DUNNET.

Neutral mass	Theoretical molecular ion mass	molecular formula	Ion formula	Compound most probable in CSF	Mean Intensity \pm SD control	Mean Intensity \pm SD Parkinson's disease	alteration in Parkinson's disease	p-value
129.04261	128.03534	C ₅ H ₇ NO ₃	[C ₅ H ₆ NO ₃] ⁻	5-Oxoproline	1.05E+06 \pm 1.09E+06	1.5E+06 \pm 1.27E+06	↑	0.0795
188.01433	187.00705	C ₇ H ₈ O ₄ S	[C ₇ H ₇ O ₄ S] ⁻	p-cresol sulfate	5.74E+04 \pm 3.23E+05	5.33E+05 \pm 1.03E+06	↑	0.0002
186.06411	185.05684	C ₇ H ₁₀ N ₂ O ₄	[C ₇ H ₉ N ₂ O ₄] ⁻	S-AMPA	1.49E+05 \pm 4.69E+05	0.0E+0 0 \pm 0.0E+0.0	↓	0.2695
192.06343	191.05616	C ₇ H ₁₂ O ₆	[C ₇ H ₁₁ O ₆] ⁻	Quinic acid	6.30E+05 \pm 1.02E+06	1.07E+06 \pm 1.3E+06	↑	0.019
260.02032	259.01305	C ₆ H ₁₂ O ₉ S	[C ₆ H ₁₁ O ₉ S] ⁻	D-Glucose-6-sulfate	4.1E+05 \pm 8.18E+05	5.54E+05 \pm 8.94E+05	↑	0.3258
163.09980	162.09253	C ₁₀ H ₁₃ NO	[C ₁₀ H ₁₂ NO] ⁻	N-Acetylphenyl-ethylamine	1.5E+04 \pm 1.48E+05	1.49E+05 \pm 4.66E+05	↑	0.0578
210.07402	209.06675	C ₇ H ₁₄ O ₇	[C ₇ H ₁₃ O ₇] ⁻	Sedoheptulose	1.31E+06 \pm 1.14E+06	8.06E+05 \pm 9.76E+05	↓	0.0701
268.07956	267.07228	C ₉ H ₁₆ O ₉	[C ₉ H ₁₅ O ₉] ⁻	α -mannosylglycerate	1.32E+06 \pm 1.49E+06	1.78E+06 \pm 1.78E+06	↑	0.1406
172.14637	171.13910	C ₁₀ H ₂₀ O ₂	[C ₁₀ H ₁₉ O ₂] ⁻	Decanoic acid	4.69E+04 \pm 2.64E+05	2.38E+05 \pm 6.42E+05	↑	0.0116
188.14116	187.13389	C ₁₀ H ₂₀ O ₃	[C ₁₀ H ₁₉ O ₃] ⁻	10-Hydroxydecanoic acid	1.67E+04 \pm 1.64E+05	1.76E+05 \pm 5.5E+05	↑	0.0129
234.16207	233.15480	C ₁₅ H ₂₂ O ₂	[C ₁₅ H ₂₁ O ₂] ⁻	Valerenic acid	8.67E+05 \pm 1.06E+06	1.23E+06 \pm 1.19E+06	↑	0.1567
304.24043	303.23316	C ₂₀ H ₃₂ O ₂	[C ₂₂ H ₃₁ O ₂] ⁻	Arachidonic acid	4.01E+05 \pm 8.42E+05	9.15E+05 \pm 1.52E+06	↑	0.0494
306.25612	305.24885	C ₂₀ H ₃₄ O ₂	[C ₂₀ H ₃₃ O ₂] ⁻	Dihomo- γ -linolenic acid	6.61E+05 \pm 1.28E+06	8.62E+05 \pm 1.19E+06	↑	0.4911
622.55332	621.54604	C ₃₉ H ₇₄ O ₅	[C ₃₉ H ₇₃ O ₅] ⁻	DG (36:1)	1.73E+06 \pm 2.23E+06	8.17E+05 \pm 1.62E+06	↓	0.0677
747.61377	746.60650	C ₄₂ H ₈₆ NO ₇ P	[C ₄₂ H ₈₅ NO ₇ P] ⁻	PC/PE	1.58E+06 \pm 1.29E+06	1.09E+06 \pm 1.24E+06	↓	0.0291

<https://doi.org/10.1371/journal.pone.0208752.t002>

with PD-markers, was obtained from the supporting material of the same publication [24]. The network was reconstructed on the full set of features with molecular formula assignment, including the 243 differentially regulated features (features selected with the ReliefF algorithm). The complete detected metabolome is assumed to provide the substrates for the (bio-) synthesis of these 243 disease markers. MDEA tests which Δm 's (biochemical reactions) connect markers to the remaining metabolome and therewith highlights probable reactions of bio-marker synthesis [24, 25]. Fisher's exact test was used to evaluate enrichment, resulting in Z-Scores and p-values. The Z-scores of $Z \approx 2$ and $Z \approx 2.5$ relate to $p \approx 0.05$ and $p \approx 0.01$, respectively. This way, MDEA addresses the differential usage patterns of molecular building blocks in the biosynthesis of PD- and Control-markers.

Results

The metabolic profiles of 31 Parkinson-patients and 95 controls were analyzed by FT-ICR-MS. A features selection was performed after the annotation of elemental formulas of the respective m/z-values in the generated data matrix. The feature selection excluded a part of the data noise and the information not related to the study design (Parkinson vs. control). The subset of

variables calculated with such algorithm was reduced to 243 m/z values. Consecutively, we wanted to test if the list of 243 m/z was capable to separate the two groups under investigation. We built a sPLS-DA analysis (Fig 1A) and an OPLS-DA (Fig 1B). Both were able to separate controls from diseased individuals [26]. This separation was even clearer with the OPLS-DA analysis, showing good values for the fitting and prediction ($R^2Y(\text{cum}) = 0.98$ and $Q^2(\text{cum}) = 0.53$. The cross validation Anova gave a p-value < 0.0001). The OPLS-DA explained 32% of variance with the first two components (the sPLS-DA explained with the three main components 16% of variance). The values of the Balanced Error Rate (BER) for the sPLS-DA model are in the supplementary S5 Table. Moreover, we have observed that in both plots (1A and 1B) the youngest patients do not cluster all together. In the clustering, we didn't find any trends for the age, meaning that the factor that drives the separation is related with the health status of the person. Among the 243 masses, we found 81 metabolites with decreasing and 162 metabolites with increasing signal intensities for PD samples relative to controls (Fig 1C), according with both models (S2 Table). The highest loadings values were chosen as the most explicative variables in the class separation. Fig 1D represents the ROC curve calculated from the first




Fig 1. The implemented statistical analysis models. A) sPLS-DA and B) OPLS-DA both validated with 7 fold cross-validation, C) compounds, which significantly distinguished PD from controls, D) and E) represented the area under the Receiver Operating Characteristic (ROC) curve and the classification error rates by which the number of components was tuned (7 cross-validation), F) compared intensities of selected lipids. expl. var., explorative variance.

<https://doi.org/10.1371/journal.pone.0208752.g001>

component of the sPLS-DA analysis. The ROC curve, calculated on the 243 subset of masses confirmed that this list could be optimal for the discrimination of the two groups. Moreover, Fig 1E represents the performance plot. It is based on t-tests for significant difference in the mean error rate between components. The error rate after the second components seems to be stabilized. Therefore, two components are sufficient to achieve a good performance.

From the subset of metabolites we investigated only the possible assigned with the KEGG database (in total are 32). Among those 32 candidates, we presented in Table 2 the most relevant from a biological point of view (all possible assignments for these most relevant metabolites are listed in S3 Table). Most of the affected compounds derived from the compound class of lipids (decanoic acid, 10-hydroxydecanoic acid, arachidonic acid, dihomono- γ -linolenic acid, diacylglycerol (DG), phosphatidylcholine (PC) and phosphatidylethanolamine (PE)). Additionally, sugar derivatives and carboxylic acids were affected.

Moreover, an ANCOVA analysis was performed to evaluate the influence of age and gender on the results. The analysis did not reveal any significant interactions between age and the main factor (Parkinson vs. control) for each of the metabolites presented in Table 2. The only significant interaction was found for gender for the Arachidonic acid ($p = 0.003$).

Based on the feature selection and the classification models results, the entire dataset (S1 Table) was analyzed by a network approach. The network was build up by connecting exact m/z -features (nodes) using mass differences (Δm) that were derived from biochemical reactions as demonstrated in Fig 2A for the conversion of 2-Ketosuccinate to 2-Ketoglutarate. The Δm 's are characterized by Z-scores, which represent the increase or decrease of a Δm 's occurrence with significantly regulated metabolic features (all the z-scores are listed in S4 Table). Fig 2B illustrates the over-represented Δm s in PD. Different compounds, involved in the cellular




Fig 2. A) theory behind the network analysis shown for a specific example, B), over-represented Δm for PD as characterized by respective Z-scores.

<https://doi.org/10.1371/journal.pone.0208752.g002>

respiration processes namely the TCA cycle, were observed increased in PD. These compounds, which are part of the TCA cycle like α -ketoglutarate and pyruvate, were increased, but also substrates for the synthesis of compounds of the TCA cycle like amino acids and breakdown products of several TCA-compounds were found over-represented in PD. Additionally, the compounds lipoic acid and vitamin B3 are over-represented MDBs, which are important for the function of pyruvate dehydrogenase.

Discussion

In this study, we investigated the metabolic profile of CSF-samples from PD patients and controls. Our approach used CSF-samples to investigate the changes due to disease. CSF is a suitable biofluids to investigate changes in neurodegenerative diseases, because it is in close contact to the brain. This biofluids is in direct contact to the extracellular space of brain parenchyma [14] and therefore metabolic changes within brain are likely to be reflected in CSF [15]. In contrast to more common targeted analysis like LC-MS, this non-targeted FT-ICR-MS analysis can be used to create new hypotheses, to evaluate as much compounds as possible, and to compare results with other metabolomic investigations already done in PD. The main aim of non-targeted determination by FT-ICR-MS is the spectral profile comparison of healthy and diseased state. Targeted approaches need a prior hypothesis, e.g. a specific compound class to determine, since only a part of the metabolome can be quantified. This application has major advantages when selected compounds have to be measured and can be used as a follow up to non-targeted methods. It has to be clear, that none of the existing techniques can cover all metabolites [27]. Therefore, to get a complete and comprehensive metabolite overview it is necessary to use several techniques and methods to cover as much metabolites as possible.

As hypothesized, we revealed several altered metabolites in PD as compared to controls. Specifically, metabolites belonging to the lipid/ fatty acid, glutathione, and energy metabolism showed a strong shift. Especially the increased level of the fatty acid arachidonic acid is associated with increased oxidative stress and neuroinflammation [28–30].

Age and gender are important factors in metabolic balance [31–33]. The patient groups investigated within this study are not matched for age and gender. Therefore, an ANCOVA was performed to evaluate the influence of both factors on the differentiation of PD and control-patients. For the parameter age we couldn't find any influence on the most significant metabolites detected in the CSF samples. In contrast to age, the differentiation between PD and control for arachidonic acid is also related to the gender. The interaction between the gender and the variable (PD vs. control) is significant ($p = 0.003$). A gender influence on arachidonic acid concentration was also ascertained by a meta-analysis of 51 publications. This gender influence was not true for other investigated fatty acids [34]. Moreover, 11 PD-patients received PD-specific medication, 2 patients had electrodes and 18 patients didn't have a medication at the time point of sample taking. Since medication of patients is too diverse this covariate was not taken into consideration.

Statistical models were applied to the achieved mass spectra for calibration. All the models gave an overall agreement, isolating a common list of important masses altered in the two different groups. The statistical analysis models sPLS-DA and OPLS-DA confirmed the good group separation according to principal components 1 and 2. Moreover, the area under the curve (ROC) showed also a high performance of the classification model, since it was calculated based on the predicted scores [23]. Additionally, the statistical analysis provided an insight into the biological characterization of PD, and the consequent confirmation of some biomarkers in the literature which are discussed in the following paragraphs.

Glutathione metabolism

5-Oxoproline is an oxidation product and therefore elevated levels are a sign of increased oxidation. It is also associated with oxidative stress [35]. 5-Oxoproline is a part of the γ -glutamyl-cycle and thus it is implicated in glutathione (GSH) -metabolism. GSH is a protective compound against oxidative stress by oxidizing to glutathione disulfide (GSSG) with simultaneous reduction of H_2O_2 [36]. A higher rate of GSH-biosynthesis is associated with decreased oxidative stress but also with higher need to remove reactive oxygen species (ROS). GSH is depleted with increasing age [37] and in neurodegeneration, especially decreased values were found in substantia nigra [38–40] and CSF [41] of PD-patients. In contrast to this, increased levels of GSH have been found in an early stage of disease, possibly for protection against further oxidative stress [37, 42]. Increased concentrations of 5-oxoproline were found in plasma of PD-patients [43]. Additionally, Wu et al. [44] found an increased urinary excretion of 5-oxoproline to be associated with a reduced availability of cysteine and glycine and hence reduced GSH-biosynthesis in vivo. A reduced GSH-biosynthesis is followed by accumulation of ROS after a short time and causes neurodegeneration. Although we did not measure GSH itself, the increased 5-oxoproline content we have found in PD seems to be associated to protection against oxidative stress in an early disease progress (duration of disease: 0.87 years).

Energy metabolism

Metabolites belonging to the energy metabolism were found within our study. We discovered increased intensities of D-glucose-6-sulfate and α -mannosylglycerate and decreased intensity of sedoheptulose in CSF of PD-patients. The metabolite α -mannosylglycerate is part of the fructose and mannose metabolism, two compounds which were also found to be increased in CSF of PD-patients [45]. These metabolites are also linked to glycolysis [46], which is increased in conditions of oxidative stress to suppress oxidative phosphorylation in mitochondria [47]. In concordance with these increased concentrations of metabolites of the fructose and mannose pathways, Ahmed et al. found another metabolite linked with this pathway. Increased concentrations of sorbitol were found in plasma of PD-patients. Additionally, Michell et al. identified increased intensity of several monosaccharides in serum [48]. The used method was not able to further differentiate in specific monosaccharides. Moreover, a study investigating especially the changes of energy metabolism in dopaminergic cells after exposure to environmental/ mitochondrial toxins (model for PD) was performed [49]. They found increased concentrations of sedoheptulose and the hexoses glucose and myoinositol. Although the direction of some shifted metabolites is inconclusive comparing the studies, a clear hint to changes in the energy metabolism due to PD is given and needs further investigation.

Fatty acids and lipid metabolism

Our investigations showed several fatty acids to be altered in PD. Quinic acid, decanoic acid, 10-hydroxydecanoic acid, valerenic acid, arachidonic acid, and dihomogamma-linolenic acid were found with increased intensities in PD. The lipid metabolism compounds DG, PC, and PE had decreased intensities in PD. Medium and long chain fatty acids (5-dodecanoate, 3-hydroxydecanoate, docosadienoate, and docosatrienoate) were also found increased in biofluids (plasma, CSF) of PD-patients by use of non-targeted metabolomic approaches [4]. Other studies also found alterations in fatty acid composition, although with decreasing intensity in PD. Trupp et al. found decreasing C16 and C18 fatty acids in plasma of PD patients [43] and Michell et al. decreased amount of octenoic acid in serum [48] indicating a possible inverse behavior of fatty acids in CSF and serum/plasma.

Especially DGLA and arachidonic acid (ARA) were investigated several times in various body fluids. Both compounds are polyunsaturated fatty acids (PUFA) present in human brain. PUFAs are vulnerable to oxidative stress due to lipid peroxidation [28, 50]. DGLA can form either anti-inflammatory compounds or pro-inflammatory ARA. Additionally, ARA is bound to membranes in brain; it is released enzymatically upon inflammation [51]. We found an increased content of DGLA and ARA in CSF of PD, which implies an elevation in pro-inflammatory characteristics. The enzymatic oxidation of ARA forms multiple pro-inflammatory metabolites [51]. A study investigated the development of the prostaglandins (PG) PGE₁ and PGE₂ (anti-inflammatory/ pro-inflammatory) after dietary DGLA intake in rat plasma [52]. The PGE₁-level and the PGE₂-level increased after DGLA-administration, but PGE₁ increase was much higher. This finding is linked to increased anti-inflammatory capacity, at least at the beginning of disease. The ARA metabolism is strictly regulated in normal brain, but any misbalance due to neuroinflammation or oxidative stress can increase ARA metabolism in the brain and can finally cause neurodegeneration [53]. Julien *et al.* [54] investigated the fatty acid profile in postmortem brain of PD and in parkinsonian monkeys by gas chromatography. They focused on fatty acids in the cortex of the brain and found a significant elevation of ARA in humans and in monkeys after administration of the drug levodopa. ARA signaling was also found to be increased in a rat model with PD [30]. Thereby, an up-regulation of the cytosolic phospholipase A₂ was found in cortex and putamen in affected rats, which is associated with elevated neuroinflammation in the brains of diseased subjects. A disease-orientated investigation studied the metabolic changes in rat brain after an intravenous Mn-injection. K. Neth *et al.* [7] found decreased DGLA-levels and nine other fatty acids and an increase in the lipid mediators PGB₁, 15-(S)-HETE and Resolvin D2, which are associated with inflammation. Our investigation showed also a significant increase of DGLA and ARA in PD (Fig 1F), which can be associated with neuroinflammation and oxidative stress. Although our results showed no marked increase in the pro-inflammatory lipid mediators, arachidonic acid seems to have a higher release from membranes due to inflammatory processes.

Additional information about reactions was provided by MDEA. The MDEA analysis showed reactions with malondialdehyde (MDA)-production over-represented in PD. A direct detection of MDA by FT-ICR-MS is impossible because of too small molecular weight and the labile character of the compound. MDA is a marker for oxidative stress and a break-down product of PUFAs. Therefore, MDA is also involved in lipid peroxidation. Several studies identified MDA as marker of PD [55]. They found increased MDA levels in plasma in an early and late disease stages. Significantly increased MDA levels in PD compared to controls were also found in erythrocytes [56] and in plasma [57]. A recent review gives an overview of the MDA-metabolism [28].

Mitochondrial dysfunction

Mitochondrial dysfunction is known to be involved in PD [58, 59]. Mitochondria produce the majority of cellular energy by oxidative phosphorylation. The 243 masses which differentiated controls and PD patients were further analyzed by MDEA to get an insight into processes involved in the disease. MDEA connected the masses within a network with specific mass differences explaining biochemical reactions and compared the abundance of each biochemical reaction in controls and PD. Our results showed over-represented metabolites associated with the TCA-cycle, as illustrated in Fig 3. We found compounds of the TCA-cycle over-represented (colored orange in Fig 3), compounds which are mandatory to synthesize compounds of the TCA-cycle (colored red in Fig 3) and also break-down products of several TCA-cycle compounds (colored purple in Fig 3). Mitochondrial dysfunction is primarily caused by ROS




Fig 3. Over-represented metabolites within the TCA cycle. Metabolites directly found with network analysis are colored orange. Metabolites indirectly found either by substrates for synthesis of the respective compound (colored red) or by break-down products of the respective compound (colored purple).

<https://doi.org/10.1371/journal.pone.0208752.g003>

generated within mitochondria, but also metabolic dysregulation [60, 61]. Various metabolomic studies found altered metabolites of the TCA cycle within analysis. An increased concentration of malate in plasma of PD-patients was found by [43] and an increased concentration of citrate in CSF by [6]. In contrast to these observations, Ahmed et al. found decreased levels of several TCA metabolites (citrate, malate, succinate, and isocitrate) in plasma [62]. The inconsistent results may be due to differing sample matrix, sampling, storage and methods used and need further clarification. Apart from the compounds within the TCA cycle, different proteins, metals and other metabolites are needed for the synthesis and function of mitochondrial enzymes. Key nutrients are iron, manganese, copper, zinc, vitamin B3 and lipoic acid [63]. The metals are important central atoms in proteins, lipoic acid and vitamin B3 are important for the function of pyruvate dehydrogenase; the enzyme catalyzes the oxidative decarboxylation of pyruvate. An analysis of CSF with capillary zone electrophoresis hyphenated with inductively coupled plasma mass spectrometry shows the compounds fumarate, malate, oxaloacetate, α-ketoglutarate, citrate and NAD, which a part of the TCA-cycle, to be associated with manganese [64]. A change of associated transition metal to the metabolites could be an amplifying factor for increased oxidative stress in PD and also for mitochondrial dysfunction. A dysregulation of the metals iron, copper, manganese, and zinc was already found within these

sample-set [65]. Thereby a dysregulation of specific ratios between different mass fractions of these metals were found to be significantly different in PD and controls. A correlation of shifted metal concentrations and metal ratios with TCA cycle compound could be beneficial to get further information regarding the relationship between metals and metabolites.

Conclusion

In conclusion, the pipeline we used gave us an understanding of the unknown space investigated. We found several metabolites in CSF of PD and controls by using the untargeted metabolomics technique FT-ICR-MS. Due to the use of multivariate statistical analysis a differentiation between PD and controls was possible. Especially metabolites of the lipid metabolism showed up to be affected due to disease. Moreover, indices of mitochondrial dysfunction and alterations of the energy metabolism were found in PD. More research effort should be directed to targeted approaches to unravel the lipid metabolism pathways affected in PD. Additionally, correlation of metal-analysis with TCA cycle products may enable further insights into disease mechanisms.

Supporting information

S1 Table. Raw data of non-targeted metabolomic investigation in CSF.
(XLS)

S2 Table. Important masses detected with the ReliefF features selection algorithm.
(XLS)

S3 Table. Most important neutral masses to distinguish between Parkinson's disease and controls with all possible assignments to respective masses.
(DOC)

S4 Table. Summary of network analysis.
(XLS)

S5 Table. Balanced Error Rate (BER).
(XLS)

Acknowledgments

The authors are thankful to the principal investigator of this study Prof. Uwe Fuhr.

Author Contributions

Conceptualization: Desiree Willkommen, Michael Schroeter, Ali Sigaroudi, Philippe Schmitt-Kopplin, Bernhard Michalke.

Data curation: Desiree Willkommen, Marianna Lucio, Franco Moritz.

Formal analysis: Desiree Willkommen, Marianna Lucio, Franco Moritz, Kirill S. Smirnov.

Investigation: Desiree Willkommen, Sara Forcisi, Basem Kanawati.

Methodology: Desiree Willkommen, Marianna Lucio, Sara Forcisi, Basem Kanawati, Philippe Schmitt-Kopplin, Bernhard Michalke.

Project administration: Desiree Willkommen, Michael Schroeter, Philippe Schmitt-Kopplin, Bernhard Michalke.

Resources: Michael Schroeter, Ali Sigaroudi, Bernhard Michalke.

Software: Franco Moritz, Kirill S. Smirnov.

Supervision: Philippe Schmitt-Kopplin, Bernhard Michalke.

Validation: Desiree Willkommen, Marianna Lucio, Franco Moritz.

Visualization: Desiree Willkommen, Marianna Lucio.

Writing – original draft: Desiree Willkommen, Marianna Lucio, Franco Moritz.

Writing – review & editing: Desiree Willkommen, Marianna Lucio, Franco Moritz, Sara Forcisi, Basem Kanawati, Michael Schroeter, Ali Sigaroudi, Philippe Schmitt-Kopplin, Bernhard Michalke.

References

1. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. *J Neurol Neurosurg Psychiatr*. 1997; 62(1):10–5. Epub 1997/01/01. PMID: [9010393](#); PubMed Central PMCID: PMC486688.
2. Miller DB, O'Callaghan JP. Biomarkers of Parkinson's disease: present and future. *Metabolism*. 2015; 64(3 Suppl 1):S40–6. <https://doi.org/10.1016/j.metabol.2014.10.030> PMID: [25510818](#); PubMed Central PMCID: PMC4721253.
3. Andersen AD, Binzer M, Stenager E, Gramsbergen JB. Cerebrospinal fluid biomarkers for Parkinson's disease—a systematic review. *Acta Neurol Scand*. 2017; 135(1):34–56. <https://doi.org/10.1111/ane.12590> PMID: [26991855](#)
4. LeWitt PA, Li J, Lu M, Guo L, Auinger P. Metabolomic biomarkers as strong correlates of Parkinson disease progression. *Neurology*. 2017; 88(9):862–9. <https://doi.org/10.1212/wnl.0000000000003663> PMID: [28179471](#)
5. Burté F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, et al. metabolic profiling of Parkinson's disease and mild cognitive impairment. *Mov Disord*. 2017; 32(6):927–32. <https://doi.org/10.1002/mds.26992> PMID: [28394042](#)
6. Wu J, Wuolikainen A, Trupp M, Jonsson P, Marklund SL, Andersen PM, et al. NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. *Metabolomics*. 2016; 12(6):101. <https://doi.org/10.1007/s11306-016-1041-6>.
7. Neth K, Lucio M, Walker A, Zorn J, Schmitt-Kopplin P, Michalke B. Changes in Brain Metallome/Metabolome Pattern due to a Single i.v. Injection of Manganese in Rats. *PLoS One*. 2015; 10(9):e0138270. <https://doi.org/10.1371/journal.pone.0138270> PMID: [26383269](#); PubMed Central PMCID: PMC4575095.
8. Neth K, Lucio M, Walker A, Kanawati B, Zorn J, Schmitt-Kopplin P, et al. Diverse Serum Manganese Species Affect Brain Metabolites Depending on Exposure Conditions. *Chem Res Toxicol*. 2015; 28(7):1434–42. <https://doi.org/10.1021/acs.chemrestox.5b00104> PMID: [26024413](#).
9. Forcisi S, Moritz F, Lucio M, Lehmann R, Stefan N, Schmitt-Kopplin P. Solutions for low and high accuracy mass spectrometric data matching: a data-driven annotation strategy in nontargeted metabolomics. *Anal Chem*. 2015; 87(17):8917–24. <https://doi.org/10.1021/acs.analchem.5b02049> PMID: [26197019](#).
10. Breitling R, Pitt AR, Barrett MP. Precision mapping of the metabolome. *Trends Biotechnol*. 2006; 24(12):543–8. <https://doi.org/10.1016/j.tibtech.2006.10.006> PMID: [17064801](#)
11. Breitling R, Ritchie S, Goodenowe D, Stewart ML, Barrett MP. Ab initio prediction of metabolic networks using Fourier transform mass spectrometry data. *Metabolomics*. 2006; 2(3):155–64. <https://doi.org/10.1007/s11306-006-0029-z> PMID: [24489532](#)
12. Havelund J, Heegaard N, Færgeman N, Gramsbergen J. Biomarker Research in Parkinson's Disease Using Metabolite Profiling. *Metabolites*. 2017; 7(3):42. <https://doi.org/10.3390/metabo7030042>.
13. Smirnov KS, Maier TV, Walker A, Heinzmann SS, Forcisi S, Martinez I, et al. Challenges of metabolomics in human gut microbiota research. *Int J Med Microbiol*. 2016; 306(5):266–79. <https://doi.org/10.1016/j.ijmm.2016.03.006> PMID: [27012595](#)
14. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol*. 2010; 6(3):131–44. <https://doi.org/10.1038/nrneurol.2010.4> PMID: [20157306](#).

15. Michalke B, Berthele A. Contribution to selenium speciation in cerebrospinal fluid samples. *J Anal At Spectrom.* 2011; 26(1):165–70. <https://doi.org/10.1039/C0JA00106F>.
16. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. *Front Cell Neurosci.* 2014; 8:369. <https://doi.org/10.3389/fncel.2014.00369> PMID: 25426023; PubMed Central PMCID: PMC4227512.
17. Lucio M, Fekete A, Frommberger M, Schmitt-Kopplin P. Metabolomics: High-Resolution Tools Offer to Follow Bacterial Growth on a Molecular Level. *Handbook of Molecular Microbial Ecology I*: John Wiley & Sons, Inc.; 2011. p. 683–95.
18. Tziotis D, Hertkorn N, Schmitt-Kopplin P. Kendrick-analogous network visualisation of ion cyclotron resonance Fourier transform mass spectra: improved options for the assignment of elemental compositions and the classification of organic molecular complexity. *Eur J Mass Spectrom.* 2011; 17(4):415–21. Epub 2011/10/19. <https://doi.org/10.1255/ejms.1135> PMID: 22006638.
19. Suhre K, Schmitt-Kopplin P. MassTRIX: mass translator into pathways. *Nucleic Acids Res.* 2008; 36 (suppl_2):W481–W4. <https://doi.org/10.1093/nar/gkn194>.
20. Wagele B, Witting M, Schmitt-Kopplin P, Suhre K. MassTRIX reloaded: combined analysis and visualization of transcriptome and metabolome data. *PLoS One.* 2012; 7(7):e39860. <https://doi.org/10.1371/journal.pone.0039860> PMID: 22815716; PubMed Central PMCID: PMC3391204.
21. Liu Y, Smirnov K, Lucio M, Gougeon RD, Alexandre H, Schmitt-Kopplin P. MetlCA: independent component analysis for high-resolution mass-spectrometry based non-targeted metabolomics. *BMC Bioinformatics.* 2016; 17(1):114. <https://doi.org/10.1186/s12859-016-0970-4>.
22. Witten IH, Frank E, Hall MA, Pal C. Data mining: practical machine learning tools and techniques. Fourth Edition. ed. Amsterdam: Elsevier; 2017. xxxii, 621 pages p.
23. Rohart F, Gautier B, Singh A, Lê Cao K-A. mixOmics: An R package for 'omics feature selection and multiple data integration. *PLOS Computational Biology.* 2017; 13(11):e1005752. <https://doi.org/10.1371/journal.pcbi.1005752> PMID: 29099853
24. Moritz F, Kaling M, Schnitzler JP, Schmitt-Kopplin P. Characterization of poplar metabolotypes via mass difference enrichment analysis. *Plant Cell Environ.* 2017; 40(7):1057–73. Epub 2016/12/13. <https://doi.org/10.1111/pce.12878> PMID: 27943315.
25. Kaling M, Schmidt A, Moritz F, Rosenkranz M, Witting M, Kasper K, et al. Mycorrhiza-Triggered Transcriptomic and Metabolomic Networks Impinge on Herbivore Fitness. *Plant Physiology.* 2018; 176 (4):2639–56. <https://doi.org/10.1104/pp.17.01810> PMID: 29439210
26. Lê Cao K-A, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. *BMC Bioinformatics.* 2011; 12:253-. <https://doi.org/10.1186/1471-2105-12-253> PubMed PMID: PMC3133555. PMID: 21693065
27. Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncz K, Xiong Y, et al. The human cerebrospinal fluid metabolome. *Journal of Chromatography B.* 2008; 871(2):164–73. <https://doi.org/10.1016/j.jchromb.2008.05.001>.
28. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev.* 2014; 2014:360438. <https://doi.org/10.1155/2014/360438> PMID: 24999379; PubMed Central PMCID: PMC4066722.
29. Rapoport SI. Arachidonic Acid and the Brain. *J Nutr.* 2008; 138(12):2515–20. <https://doi.org/10.1093/jn/138.12.2515> PMID: 19022981; PubMed Central PMCID: PMC3415870.
30. Lee HJ, Bazinet RP, Rapoport SI, Bhattacharjee AK. Brain arachidonic acid cascade enzymes are up-regulated in a rat model of unilateral Parkinson disease. *Neurochem Res.* 2010; 35(4):613–9. <https://doi.org/10.1007/s11064-009-0106-6> PMID: 19997776; PubMed Central PMCID: PMC2836388.
31. Yoshii F, Barker WW, Chang JY, Loewenstein D, Apicella A, Smith D, et al. Sensitivity of Cerebral Glucose Metabolism to Age, Gender, Brain Volume, Brain Atrophy, and Cerebrovascular Risk Factors. *Journal of Cerebral Blood Flow & Metabolism.* 1988; 8(5):654–61. <https://doi.org/10.1038/jcbfm.1988.112> PMID: 3417794.
32. Molnar D, Schutz Y. The effect of obesity, age, puberty and gender on resting metabolic rate in children and adolescents. *European journal of pediatrics.* 1997; 156(5):376–81. Epub 1997/05/01. PMID: 9177980.
33. Lazzer S, Bedogni G, Lafortuna CL, Marazzi N, Busti C, Galli R, et al. Relationship Between Basal Metabolic Rate, Gender, Age, and Body Composition in 8,780 White Obese Subjects. *Obesity.* 2010; 18 (1):71–8. <https://doi.org/10.1038/oby.2009.162> PMID: 19478787
34. Lohner S, Fekete K, Marosvolgyi T, Decsi T. Gender differences in the long-chain polyunsaturated fatty acid status: systematic review of 51 publications. *Annals of nutrition & metabolism.* 2013; 62(2):98–112. Epub 2013/01/19. <https://doi.org/10.1159/000345599> PMID: 23327902.

35. Cassol E, Misra V, Dutta A, Morgello S, Gabuzda D. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. *AIDS*. 2014; 28(11):1579–91. <https://doi.org/10.1097/QAD.0000000000000303> PMID: 24752083; PubMed Central PMCID: PMC4086755.
36. Aoyama K, Nakaki T. Impaired glutathione synthesis in neurodegeneration. *Int J Mol Sci*. 2013; 14(10):21021–44. <https://doi.org/10.3390/ijms141021021> PMID: 24145751; PubMed Central PMCID: PMC3821656.
37. Maher P. The effects of stress and aging on glutathione metabolism. *Ageing Res Rev*. 2005; 4(2):288–314. <https://doi.org/10.1016/j.arr.2005.02.005> PMID: 15936251
38. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. *Ann Neurol*. 1994; 36(3):356–61. <https://doi.org/10.1002/ana.410360306> PMID: 8080243.
39. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. *Ann Neurol*. 1994; 36(3):348–55. <https://doi.org/10.1002/ana.410360305> PMID: 8080242.
40. Pearce RKB, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. *Journal of neural transmission*. 1997; 104(6):661–77. <https://doi.org/10.1007/bf01291884>.
41. LeWitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L, et al. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. *Mov Disord*. 2013; 28(12):1653–60. <https://doi.org/10.1002/mds.25555> PMID: 23873789.
42. Rae CD. A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain ¹H Magnetic Resonance Spectra. *Neurochem Res*. 2014; 39(1):1–36. <https://doi.org/10.1007/s11064-013-1199-5> PMID: 24258018
43. Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. *J Parkinsons Dis*. 2014; 4(3):549–60. <https://doi.org/10.3233/JPD-140389> PMID: 24927756.
44. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione Metabolism and Its Implications for Health. *J Nutr*. 2004; 134(3):489–92. <https://doi.org/10.1093/jn/134.3.489> PMID: 14988435
45. Trezzi JP, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W, et al. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. *Mov Disord*. 2017; 32(10):1401–8. <https://doi.org/10.1002/mds.27132> PMID: 28843022.
46. Izumi Y, Zorumski CF. Glial–neuronal interactions underlying fructose utilization in rat hippocampal slices. *Neuroscience*. 2009; 161(3):847–54. <https://doi.org/10.1016/j.neuroscience.2009.04.008> PMID: 19362122
47. Mazzio E, Soliman KFA. The Role of Glycolysis and Gluconeogenesis in the Cytoprotection of Neuroblastoma Cells against 1-Methyl 4-Phenylpyridinium Ion Toxicity. *NeuroToxicology*. 2003; 24(1):137–47. [https://doi.org/10.1016/S0161-813X\(02\)00110-9](https://doi.org/10.1016/S0161-813X(02)00110-9) PMID: 12564389
48. Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in Parkinson's disease. *Metabolomics*. 2008; 4(3):191. <https://doi.org/10.1007/s11306-008-0111-9>.
49. Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N, et al. Alterations in Energy/Redox Metabolism Induced by Mitochondrial and Environmental Toxins: A Specific Role for Glucose-6-Phosphate-Dehydrogenase and the Pentose Phosphate Pathway in Paraquat Toxicity. *ACS Chemical Biology*. 2014; 9(9):2032–48. <https://doi.org/10.1021/cb400894a> PMID: 24937102
50. Liu X, Yamada N, Maruyama W, Osawa T. Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease. *The Journal of biological chemistry*. 2008; 283(50):34887–95. <https://doi.org/10.1074/jbc.M805682200> PMID: 18922792; PubMed Central PMCID: PMC3259879.
51. Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. *Nat Rev Neurosci*. 2014; 15(12):771–85. <https://doi.org/10.1038/nrn3820> PMID: 25387473.
52. Umeda-Sawada R, Fujiwara Y, Ushiyama I, Sagawa S, Morimitsu Y, Kawashima H, et al. Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats. *Biosci Biotechnol Biochem*. 2006; 70(9):2121–30. <https://doi.org/10.1271/bbb.60057> PMID: 16960355.
53. Bosetti F. Arachidonic Acid Metabolism in Brain Physiology and Pathology: Lessons from Genetically Altered Mouse Models. *J Neurochem*. 2007; 102(3):577–86. <https://doi.org/10.1111/j.1471-4159.2007.04558.x> PubMed PMID: PMC2084377. PMID: 17403135
54. Julien C, Berthiaume L, Hadj-Tahar A, Rajput AH, Bedard PJ, Di Paolo T, et al. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. *Neurochem Int*. 2006; 48(5):404–14. <https://doi.org/10.1016/j.neuint.2005.12.002> PMID: 16442670.

55. de Farias CC, Maes M, Bonifácio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, et al. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new drug targets. *Neurosci Lett*. 2016; 617(Supplement C):66–71. <https://doi.org/10.1016/j.neulet.2016.02.011>.
56. Sunday O, Adekunle M, Temitope O, Richard A, Samuel A, Olufunminkyi A, et al. Alteration in antioxidants level and lipid peroxidation of patients with neurodegenerative diseases {Alzheimer's disease and Parkinson disease}. *Int J Nutr Pharm Neurol Dis*. 2014; 4(3):146–52. <https://doi.org/10.4103/2231-0738.132671>.
57. Sanyal J, Bandyopadhyay SK, Banerjee TK, Mukherjee SC, Chakraborty DP, Ray BC, et al. Plasma levels of lipid peroxides in patients with Parkinson's disease. *Eur Rev Med Pharmacol Sci*. 2009; 13(2):129–32. Epub 2009/06/09. PMID: [19499848](https://pubmed.ncbi.nlm.nih.gov/19499848/).
58. Anandhan A, Jacome MS, Lei S, Hernandez-Franco P, Pappa A, Panayiotidis MI, et al. Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. *Brain Res Bull*. 2017; 133:12–30. <https://doi.org/10.1016/j.brainresbull.2017.03.009> PMID: [28341600](https://pubmed.ncbi.nlm.nih.gov/28341600/); PubMed Central PMCID: PMC5555796.
59. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial Complex I Deficiency in Parkinson's Disease. *J Neurochem*. 1990; 54(3):823–7. <https://doi.org/10.1111/j.1471-4159.1990.tb02325.x> PMID: [2154550](https://pubmed.ncbi.nlm.nih.gov/2154550/)
60. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. *Exp Mol Pathol*. 2007; 83(1):84–92. <https://doi.org/10.1016/j.yexmp.2006.09.008> PubMed PMID: WOS:000247716800013. PMID: [17239370](https://pubmed.ncbi.nlm.nih.gov/17239370/)
61. Moon HE, Paek SH. Mitochondrial Dysfunction in Parkinson's Disease. *Exp Neurobiol*. 2015; 24(2):103–16. <https://doi.org/10.5607/en.2015.24.2.103> PubMed PMID: PMC4479806. PMID: [26113789](https://pubmed.ncbi.nlm.nih.gov/26113789/)
62. Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. *Journal of biomedical science*. 2009; 16:63. Epub 2009/07/15. <https://doi.org/10.1186/1423-0127-16-63> PMID: [19594911](https://pubmed.ncbi.nlm.nih.gov/19594911/); PubMed Central PMCID: PMC2720938.
63. Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. *Mol Aspects Med*. 2005; 26(4–5):363–78. Epub 2005/08/17. <https://doi.org/10.1016/j.mam.2005.07.007> PMID: [16102804](https://pubmed.ncbi.nlm.nih.gov/16102804/).
64. Michalke B, Berthele A, Mistriotis P, Ochsenkühn-Petropoulou M, Halbach S. Manganese speciation in human cerebrospinal fluid using CZE coupled to inductively coupled plasma MS. *Electrophoresis*. 2007; 28(9):1380–6. <https://doi.org/10.1002/elps.200600686> PMID: [17377947](https://pubmed.ncbi.nlm.nih.gov/17377947/)
65. Willkommen D, Lucio M, Schmitt-Kopplin P, Gazzaz M, Schroeter M, Sigaroudi A, et al. Species fractionation in a case-control study concerning Parkinson's disease: Cu-amino acids discriminate CSF of PD from controls. *J Trace Elem Med Biol*. 2018. <https://doi.org/10.1016/j.jtemb.2018.01.005>.